ANTICANCER ACTIVITY OF CALANONE ON HeLa CELL LINE

Heny Ekowati; Indwiani Astuti; Mustofa Mustofa

doi:10.22146/ijc.21467

ANTICANCER ACTIVITY OF CALANONE ON HeLa CELL LINE

https://doi.org/10.22146/ijc.21467

Heny Ekowati^(1*), Indwiani Astuti⁽²⁾, Mustofa Mustofa⁽³⁾

(1) Department of Pharmacy, Faculty of Medicine and Health Sciences, Jenderal Soedirman University, Karangwangkal, Purwokerto
(2) Department of Pharmacology and Toxicology, Faculty of Medicine, Universitas Gadjah Mada, Jl. Sekip Utara, Yogyakarta
(3) Department of Pharmacology and Toxicology, Faculty of Medicine, Universitas Gadjah Mada, Jl. Sekip Utara, Yogyakarta
(*) Corresponding Author

Abstract

Calanone (coumarin derivate compound), isolated from Calophyllum sp. had been shown to have cytotoxic activity on leukemia L1210 cell line with IC₅₀ = 59.40 mg/mL. Calanone presumed have anticancer activity on HeLa cervical carcinoma cell. This study was conducted to investigate the cytotoxic and apoptotic activity of calanone and its effect to p53 and p21 expression on HeLa cervical carcinoma cell. Cytotoxic assay of calanone was performed on HeLa cell line, using MTT assay. Apoptotic assay was performed on HeLa cell line incubated with calanone for 24 h, by immunofluororescence method, using fluorochromes ethidium bromide and acridine orange. Expression of p53 was examined on HeLa cell line, by PCR with p53 wild-type primer. Expression of p21 was examined on HeLa cell line, by immunohistochemistry method. 5-fluorourasil was used as positive control in cytotoxic, apoptotic assay, and p53 expression. The result showed that calanone has cytotoxic activity on HeLa cell line, with IC₅₀= 22.887 mg/mL, caused cytotoxicity through apoptotic mechanism, increase p53 tumor suppressor gene expression, while the p21 expression test showed a negative result.

Keywords

Calanone; cytotoxic; HeLa cell line

Full Text:

Full Text PDF

References

[1] Indonesia Ministry of Health, 2007, Indonesia Health Profile 2005, Jakarta.

[2] Young, R.C., 2004, Gynecologic Malignancies in Harrison’s Principles of Internal Medicine, 16^th ed., McGraw-Hill, New York.

[3] Denny, W.A., 2002, The Contribution of Synthetic Organic Chemistry to Anticancer Drug Development in Anticancer Drug Development. Oxford-United Kingdom.

[4] Kostova, I., 2005, Curr. Med. Chem., 5, 1, 29–46.

[5] Chasani, M., 2002, Synthesis of calanone derivates and biology activity test, Thesis, University of Indonesia, Jakarta

[6] Iswanto, P., Chasani, M., and Vaulina, E., 2007, Synthesis of calanone derivatives as antileukemia compound with QSAR approach (Quantitative structure-activity relationship), Research report for research institute, Jenderal Soedirman University.

[7] Yin, L., Ohno, T., Weichselbaum, R., Kharbanda, S., and Kufe, D., 2001, Mol. Cancer Ther., 1, 1, 43–48

[8] Akca, H., and Özefi, O.D., 2002, Turk J. Biol., 26, 145-150.

[9] Corwin, E.J., 2008, Handbook of Pathophysiology, 3^rd ed., Lippincott Williams & Wilkins, Philadelphia.

[10] Rugo, H.S., 2006, Cancer in Current Medical Diagnosis and Treatment, 45^th Ed., Eds. Tierney, L., McPhee, S.J., and Papadakis, M., McGraw-Hill-New York.

[11] Kubbutat, M.H.G., Ludwig, R.L., Ashcroft, M., and Vousden, K.H., 1998, Moll. Cell. Biol., 18, 10, 5690–5698.

[12] Szymanska, K., and Hainaut, P., 2003, Acta Biochim. Pol., 50, 1, 231–238.

[13] Nicolantonio, F.D., Mercer, S.J., Knight, L.A., Gabriel, F.G., Whitehouse, P.A., Sharma, S., Fernando, A., Glaysher, S., Palma, S.D., Johnson, P., Somers, S.S., Toh, S., Higgins, B., Lamont, A., Gulliford, T., Hurren, J., Yiangou, C., and Cree, I.A., 2005, BMC Cancer, 5, 78.

[14] Swain, S.M., Lippman, M.E., Egan, E.F., Drake, J.C., Steinberg, S.M., and Allegra, C.J., 1989, J. Clin. Oncol., 7, 7, 890-899.

[15] Chu, E., Koeller, D.M., Johnston, P.G., Zinn, S., and Allegra, C.J., 1993, Mol. Pharmacol., 43, 4, 527–533.

[16] Oren, M., and Rotter, V., 1999, Cell. Mol. Life Sci., 55, 1, 9–11.

[17] Vogelstein, B., Lane, D., and Levine, A., 2000, Nature, 408, 307–310.

DOI: https://doi.org/10.22146/ijc.21467